Related Experiment Video
Updated: Feb 24, 2026

A Rabbit Aortic Valve Stenosis Model Induced by Direct Balloon Injury
Published on: March 31, 2023
Update on bicuspid aortic valve aortopathy
Evaldas Girdauskas1, Johannes Petersen
1Department of Cardiovascular Surgery, University Heart Center, Hamburg, Germany.
Insights
New biomarkers show promise for predicting thoracic aortic aneurysm progression in patients with bicuspid aortic valve (BAV) disease. Combining these with imaging and risk factors can improve diagnosis and care.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Biomarker Discovery
Background:
- Bicuspid aortic valve (BAV) associated aortopathy treatment remains controversial.
- Current research focuses on predicting disease progression and adverse aortic events.
Purpose of the Study:
- To summarize recent evidence on predicting aortopathy progression in BAV disease.
- To identify novel markers for adverse aortic events.
Main Methods:
- Literature review of recent studies.
- Analysis of hemodynamic and blood-born biomarkers.
- Exploration of genetic analyses.
Main Results:
- Hemodynamic markers are key to understanding BAV-associated aortopathy progression.
- Blood-born biomarkers offer a promising approach for predicting adverse aortic events.
- Genetic factors are under investigation.
Conclusions:
- Serological biomarkers are valuable for screening and predicting thoracic aortic aneurysmal disease.
- Integrating biomarkers with rheological imaging and risk factors enhances diagnostic accuracy and cost-effectiveness for BAV-associated aortopathy.
Purpose Of Review:
The appropriate treatment of bicuspid aortic valve (BAV)-associated aortopathy is still controversial. We aimed to summarize recent evidence from the literature that focused on the prediction of aortopathy progression and adverse aortic events.
Recent Findings:
Following the detailed description of valvulo-aortic phenotypes in BAV disease in the previous imaging studies, the most current research focused on the definition of hemodynamic markers that may affect the progression of BAV-associated aortopathy and search for blood-born biomarkers to improve the prediction of adverse aortic events. Furthermore, genetic analyses are ongoing and some preliminary data will be presented.
Summary:
Serological biomarkers are a novel and promising diagnostic tool for screening thoracic aortic aneurysmal disease and prediction future adverse aortic events. In combination with rheological imaging as well as traditional risk factors diagnostic accuracy and cost-effectiveness of care in BAV-associated aortopathy will improve significantly. VIDEO ABSTRACT: http://links.lww.com/HCO/A44.
More Related Videos
04:30Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
Published on: February 4, 2021
06:51Author Spotlight: Development of a Minimally Invasive Large-Animal Model for Reliable and Reproducible Cardiovascular Research
Published on: October 20, 2023
Related Concept Videos
Aortic Regurgitation I: Introduction
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Aneurysm I: Introduction
Aortic Regurgitation III: Medical Management
Mitral Stenosis I: Introduction